Long-Term Injectable Drug Delivery Market Size and Forecast 2021 - 2034, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Formulation Packaging, Therapeutic Application, Route of Administration and Geography

Description

List of Tables

The long-term injectable drug delivery market is projected to reach US$ 15.21 billion by 2034 from US$ 7.07 billion in 2025. The market is estimated to register a CAGR of 8.9% during 2026-2034. Major factors driving market growth include the increasing prevalence of chronic and psychiatric disorders requiring long-term pharmacotherapy, advancements in drug delivery technologies, and the rising need to improve medication adherence and reduce dosing frequency that promote long-term injectable drug delivery utilization. Further, increased demand for long-acting biologics and biosimilars in autoimmune and oncology will likely boost the market during the forecast period. However, high complexity of development and manufacturing are among the deterrents of market.

Technological advancements in long-term injectable drug delivery have revolutionized pharmacotherapy by enabling precise, sustained drug release over extended periods. Advanced drug delivery systems maintain stable plasma levels while accommodating complex molecules such as peptides, biologics, and emerging mRNA-based therapies. Key innovations include microencapsulation using biodegradable poly(lactic-co-glycolic acid) (PLGA) polymers to form microspheres, nanoparticles for enhanced stability and targeting, in-situ forming depots that solidify post-injection, and ultra-long-acting suspensions that provide release for months. These systems overcome limitations of traditional oral or short-acting injectables by protecting sensitive compounds from rapid degradation and ensuring zero-order or controlled release kinetics.

Prominent FDA-approved examples illustrate this progress. Lupron Depot (leuprolide acetate), a PLGA microsphere formulation, delivers the peptide hormone agonist for up to six months in prostate cancer and endometriosis treatment, demonstrating how microencapsulation achieves consistent gonadotropin-releasing hormone suppression with reduced dosing frequency. Risperdal Consta employs PLGA microspheres for risperidone, providing monthly intramuscular release for schizophrenia management and improving adherence over daily orals. In-situ forming depots such as Eligard (leuprolide) create a subcutaneous implant upon injection, solidifying to control release. Nanoparticle and nanosuspension technologies power products such as Invega Trinza (paliperidone palmitate), an ultra-long-acting formulation offering three-month dosing for psychiatric disorders via nanocrystal engineering that ensures prolonged absorption.

These platforms also extend to biologics and support mRNA applications through lipid nanoparticles (LNPs), which protect and deliver large, fragile molecules such as proteins or mRNA for vaccines and therapeutics, enabling cellular uptake and sustained expression. As research advances toward even longer durations and broader applicability for biologics and mRNA constructs, these innovations promise greater patient convenience, enhanced therapeutic efficacy, and expanded treatment options for chronic conditions requiring reliable, long-term drug exposure.

The comparative company analysis evaluates and categorizes the Long-Term Injectable Drug Delivery market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global Long-Term Injectable Drug Delivery market. The key market players are Becton Dickinson and Co, Schott AG, Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc., Terumo Corp, SHL Medical, Ypsomed Holding AG, Owen Mumford Ltd, and AptarGroup Inc.

In terms of formulation packaging (ready-to-use), the long-term injectable drug delivery market is bifurcated into ampoules, vials, cartridges, bottles. The vials segment held a larger market share in 2025. Vials are experiencing strong growth in the formulation packaging segment because they can store diverse injectable medications, which include biologic and vaccine products. The products provide exceptional chemical durability and protection from contamination.

In terms of therapeutic application, the long-term injectable drug delivery market is bifurcated diabetes, oncology, auto-immune disorders, cardiovascular diseases, infectious diseases, pain management, other therapeutic application. The diabetes segment held a larger market share in 2025. Rising global diabetes prevalence, strong demand for long-acting insulin and GLP-1 therapies, improved patient adherence, reduced dosing frequency, and continuous innovation in sustained-release formulations drive segment growth.

In terms of route of administration, the long-term injectable drug delivery market is bifurcated into sub-cutaneous, intramuscular, intravenous, other route of administration. The sub-cutaneous segment held a larger market share in 2025. Ease of self-administration, reduced need for clinical supervision, improved patient comfort, compatibility with biologics, and growing adoption of wearable and auto-injector systems support strong preference for subcutaneous delivery.

In terms of route of usability, the long-term injectable drug delivery market is bifurcated into disposable injectors, re-usable injectors. The disposable injectors segment held a larger market share in 2025. Convenience, reduced risk of cross-contamination, no maintenance requirements, ease of use, and increasing demand for home-based care solutions contribute to higher adoption of disposable injector systems.

Based on end user, the long-term injectable drug delivery market is categorized into pharmaceutical and biopharma companies, CMOs and CDMOs. The pharmaceutical and biopharma companies segment held a larger share of the market in 2025. Strong R&D capabilities, extensive drug pipelines, high investment in long-acting formulations, established manufacturing infrastructure, and strategic collaborations enable pharmaceutical and biopharma companies to lead market adoption and commercialization.

Companies operating in the long-term injectable drug delivery market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key Long-Term Injectable Drug Delivery market players are listed below.

In March 2026, SHL Medical AG, the global leader in advanced drug delivery solutions, announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science. The collaboration will provide end-to-end offering of sterile fill-finish and device final assembly at Thermo Fisher?s site in Ridgefield, New Jersey, USA.

In January 2026, BD and Ypsomed announced an enhanced collaboration to develop a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe compatible with Ypsomed's YpsoMate 5.5 autoinjector platform. This innovation aims to support large-volume, high-viscosity biologic self-injection by improving flow efficiency and reducing injection time. The move responds to growing demand for patient-friendly self-administration of complex therapies. Development and feasibility samples are expected by mid-2026.

Product Code: TIPRE00043136

1. Executive Summary

1.1 Analyst Market Outlook
1.2 Market Attractiveness

2. Long-Term Injectable Drug Delivery Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Force Analysis
2.5 PEST Analysis
2.6 Import-Export Analysis for Key Countries (As per the nearest HS Code)
- 2.6.1 Import-Export Analysis for Key Countries
2.7 Impact of Artificial Intelligence (AI)
2.8 Product or Technology Roadmap
2.9 Sustainability and ESG Trends
2.10 Patent Analysis
2.11 Regulatory Framework

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. Long-Term Injectable Drug Delivery Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints

5. Long-Term Injectable Drug Delivery Market - Global Market Analysis

5.1 Long-Term Injectable Drug Delivery Market Revenue (US$ Million), 2021-2034
5.2 Long-Term Injectable Drug Delivery Market Forecast and Analysis

6. Long-Term Injectable Drug Delivery Market Revenue Analysis - Formulation Packaging (ready-to-use)

6.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by Formulation Packaging (ready-to-use)
- 6.1.1 Ampoules
  - 6.1.1.1 Overview
  - 6.1.1.2 Ampoules: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 6.1.2 Vials
  - 6.1.2.1 Overview
  - 6.1.2.2 Vials: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 6.1.3 Cartridges
  - 6.1.3.1 Overview
  - 6.1.3.2 Cartridges: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 6.1.4 Bottles
  - 6.1.4.1 Overview
  - 6.1.4.2 Bottles: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)

7. Long-Term Injectable Drug Delivery Market Revenue Analysis - Therapeutic Application

7.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by Therapeutic Application
- 7.1.1 Diabetes
  - 7.1.1.1 Overview
  - 7.1.1.2 Diabetes: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.2 Oncology
  - 7.1.2.1 Overview
  - 7.1.2.2 Oncology: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.3 Auto-Immune Disorders
  - 7.1.3.1 Overview
  - 7.1.3.2 Auto-Immune Disorders: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.4 Cardiovascular Diseases
  - 7.1.4.1 Overview
  - 7.1.4.2 Cardiovascular Diseases: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.5 Infectious Diseases
  - 7.1.5.1 Overview
  - 7.1.5.2 Infectious Diseases: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.6 Pain Management
  - 7.1.6.1 Overview
  - 7.1.6.2 Pain Management: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 7.1.7 Others
  - 7.1.7.1 Overview
  - 7.1.7.2 Others: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)

8. Long-Term Injectable Drug Delivery Market Revenue Analysis - Route Of Administration

8.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by Route Of Administration
- 8.1.1 Subcutaneous
  - 8.1.1.1 Overview
  - 8.1.1.2 Subcutaneous: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 8.1.2 Intramuscular
  - 8.1.2.1 Overview
  - 8.1.2.2 Intramuscular: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 8.1.3 Intravenous
  - 8.1.3.1 Overview
  - 8.1.3.2 Intravenous: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 8.1.4 Others
  - 8.1.4.1 Overview
  - 8.1.4.2 Others: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)

9. Long-Term Injectable Drug Delivery Market Revenue Analysis - Usability

9.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by Usability
- 9.1.1 Disposable Injectors
  - 9.1.1.1 Overview
  - 9.1.1.2 Disposable Injectors: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 9.1.2 Re-usable Injectors
  - 9.1.2.1 Overview
  - 9.1.2.2 Re-usable Injectors: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)

10. Long-Term Injectable Drug Delivery Market Revenue Analysis - End User

10.1 Long-Term Injectable Drug Delivery Market Forecasts and Analysis by End User
- 10.1.1 Pharmaceutical and Biopharma Companies
  - 10.1.1.1 Overview
  - 10.1.1.2 Pharmaceutical and Biopharma Companies: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)
- 10.1.2 CMOs and CDMOs
  - 10.1.2.1 Overview
  - 10.1.2.2 CMOs and CDMOs: Long-Term Injectable Drug Delivery Market - Revenue, 2021-2034 (US$ Million)

11. Long-Term Injectable Drug Delivery Market - Geographical Analysis

11.1 North America
- 11.1.1 North America Long-Term Injectable Drug Delivery Market Overview
- 11.1.2 North America: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.1.3 North America: Long-Term Injectable Drug Delivery Market - By Segmentation
  - 11.1.3.1 Formulation Packaging (ready-to-use)
  - 11.1.3.2 Therapeutic Application
  - 11.1.3.3 Route Of Administration
  - 11.1.3.4 Usability
  - 11.1.3.5 End User
- 11.1.4 North America: Long-Term Injectable Drug Delivery Market Breakdown by Countries
  - 11.1.4.1 United States Market
    - 11.1.4.1.1 United States: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.1.4.1.2 United States: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.4.1.2.1 Formulation Packaging (ready-to-use)
      - 11.1.4.1.2.2 Therapeutic Application
      - 11.1.4.1.2.3 Route Of Administration
      - 11.1.4.1.2.4 Usability
      - 11.1.4.1.2.5 End User
  - 11.1.4.2 Canada Market
    - 11.1.4.2.1 Canada: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.1.4.2.2 Canada: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.4.2.2.1 Formulation Packaging (ready-to-use)
      - 11.1.4.2.2.2 Therapeutic Application
      - 11.1.4.2.2.3 Route Of Administration
      - 11.1.4.2.2.4 Usability
      - 11.1.4.2.2.5 End User
  - 11.1.4.3 Mexico Market
    - 11.1.4.3.1 Mexico: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.1.4.3.2 Mexico: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.4.3.2.1 Formulation Packaging (ready-to-use)
      - 11.1.4.3.2.2 Therapeutic Application
      - 11.1.4.3.2.3 Route Of Administration
      - 11.1.4.3.2.4 Usability
      - 11.1.4.3.2.5 End User
11.2 Europe
- 11.2.1 Europe Long-Term Injectable Drug Delivery Market Overview
- 11.2.2 Europe: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.2.3 Europe: Long-Term Injectable Drug Delivery Market - By Segmentation
  - 11.2.3.1 Formulation Packaging (ready-to-use)
  - 11.2.3.2 Therapeutic Application
  - 11.2.3.3 Route Of Administration
  - 11.2.3.4 Usability
  - 11.2.3.5 End User
- 11.2.4 Europe: Long-Term Injectable Drug Delivery Market Breakdown by Countries
  - 11.2.4.1 Germany Market
    - 11.2.4.1.1 Germany: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.2.4.1.2 Germany: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.2.4.1.2.1 Formulation Packaging (ready-to-use)
      - 11.2.4.1.2.2 Therapeutic Application
      - 11.2.4.1.2.3 Route Of Administration
      - 11.2.4.1.2.4 Usability
      - 11.2.4.1.2.5 End User
  - 11.2.4.2 United Kingdom Market
    - 11.2.4.2.1 United Kingdom: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.2.4.2.2 United Kingdom: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.2.4.2.2.1 Formulation Packaging (ready-to-use)
      - 11.2.4.2.2.2 Therapeutic Application
      - 11.2.4.2.2.3 Route Of Administration
      - 11.2.4.2.2.4 Usability
      - 11.2.4.2.2.5 End User
  - 11.2.4.3 France Market
    - 11.2.4.3.1 France: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.2.4.3.2 France: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.2.4.3.2.1 Formulation Packaging (ready-to-use)
      - 11.2.4.3.2.2 Therapeutic Application
      - 11.2.4.3.2.3 Route Of Administration
      - 11.2.4.3.2.4 Usability
      - 11.2.4.3.2.5 End User
  - 11.2.4.4 Spain Market
    - 11.2.4.4.1 Spain: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.2.4.4.2 Spain: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.2.4.4.2.1 Formulation Packaging (ready-to-use)
      - 11.2.4.4.2.2 Therapeutic Application
      - 11.2.4.4.2.3 Route Of Administration
      - 11.2.4.4.2.4 Usability
      - 11.2.4.4.2.5 End User
  - 11.2.4.5 Italy Market
    - 11.2.4.5.1 Italy: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.2.4.5.2 Italy: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.2.4.5.2.1 Formulation Packaging (ready-to-use)
      - 11.2.4.5.2.2 Therapeutic Application
      - 11.2.4.5.2.3 Route Of Administration
      - 11.2.4.5.2.4 Usability
      - 11.2.4.5.2.5 End User
  - 11.2.4.6 Rest of Europe Market
    - 11.2.4.6.1 Rest of Europe: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.2.4.6.2 Rest of Europe: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.2.4.6.2.1 Formulation Packaging (ready-to-use)
      - 11.2.4.6.2.2 Therapeutic Application
      - 11.2.4.6.2.3 Route Of Administration
      - 11.2.4.6.2.4 Usability
      - 11.2.4.6.2.5 End User
11.3 Asia Pacific
- 11.3.1 Asia Pacific Long-Term Injectable Drug Delivery Market Overview
- 11.3.2 Asia Pacific: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.3.3 Asia Pacific: Long-Term Injectable Drug Delivery Market - By Segmentation
  - 11.3.3.1 Formulation Packaging (ready-to-use)
  - 11.3.3.2 Therapeutic Application
  - 11.3.3.3 Route Of Administration
  - 11.3.3.4 Usability
  - 11.3.3.5 End User
- 11.3.4 Asia Pacific: Long-Term Injectable Drug Delivery Market Breakdown by Countries
  - 11.3.4.1 China Market
    - 11.3.4.1.1 China: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.3.4.1.2 China: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.3.4.1.2.1 Formulation Packaging (ready-to-use)
      - 11.3.4.1.2.2 Therapeutic Application
      - 11.3.4.1.2.3 Route Of Administration
      - 11.3.4.1.2.4 Usability
      - 11.3.4.1.2.5 End User
  - 11.3.4.2 Japan Market
    - 11.3.4.2.1 Japan: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.3.4.2.2 Japan: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.3.4.2.2.1 Formulation Packaging (ready-to-use)
      - 11.3.4.2.2.2 Therapeutic Application
      - 11.3.4.2.2.3 Route Of Administration
      - 11.3.4.2.2.4 Usability
      - 11.3.4.2.2.5 End User
  - 11.3.4.3 India Market
    - 11.3.4.3.1 India: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.3.4.3.2 India: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.3.4.3.2.1 Formulation Packaging (ready-to-use)
      - 11.3.4.3.2.2 Therapeutic Application
      - 11.3.4.3.2.3 Route Of Administration
      - 11.3.4.3.2.4 Usability
      - 11.3.4.3.2.5 End User
  - 11.3.4.4 Australia Market
    - 11.3.4.4.1 Australia: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.3.4.4.2 Australia: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.3.4.4.2.1 Formulation Packaging (ready-to-use)
      - 11.3.4.4.2.2 Therapeutic Application
      - 11.3.4.4.2.3 Route Of Administration
      - 11.3.4.4.2.4 Usability
      - 11.3.4.4.2.5 End User
  - 11.3.4.5 South Korea Market
    - 11.3.4.5.1 South Korea: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.3.4.5.2 South Korea: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.3.4.5.2.1 Formulation Packaging (ready-to-use)
      - 11.3.4.5.2.2 Therapeutic Application
      - 11.3.4.5.2.3 Route Of Administration
      - 11.3.4.5.2.4 Usability
      - 11.3.4.5.2.5 End User
  - 11.3.4.6 Rest of Asia Pacific Market
    - 11.3.4.6.1 Rest of Asia Pacific: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.3.4.6.2 Rest of Asia Pacific: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.3.4.6.2.1 Formulation Packaging (ready-to-use)
      - 11.3.4.6.2.2 Therapeutic Application
      - 11.3.4.6.2.3 Route Of Administration
      - 11.3.4.6.2.4 Usability
      - 11.3.4.6.2.5 End User
11.4 Middle East and Africa
- 11.4.1 Middle East and Africa Long-Term Injectable Drug Delivery Market Overview
- 11.4.2 Middle East and Africa: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.4.3 Middle East and Africa: Long-Term Injectable Drug Delivery Market - By Segmentation
  - 11.4.3.1 Formulation Packaging (ready-to-use)
  - 11.4.3.2 Therapeutic Application
  - 11.4.3.3 Route Of Administration
  - 11.4.3.4 Usability
  - 11.4.3.5 End User
- 11.4.4 Middle East and Africa: Long-Term Injectable Drug Delivery Market Breakdown by Countries
  - 11.4.4.1 Saudi Arabia Market
    - 11.4.4.1.1 Saudi Arabia: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.4.4.1.2 Saudi Arabia: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.4.4.1.2.1 Formulation Packaging (ready-to-use)
      - 11.4.4.1.2.2 Therapeutic Application
      - 11.4.4.1.2.3 Route Of Administration
      - 11.4.4.1.2.4 Usability
      - 11.4.4.1.2.5 End User
  - 11.4.4.2 South Africa Market
    - 11.4.4.2.1 South Africa: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.4.4.2.2 South Africa: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.4.4.2.2.1 Formulation Packaging (ready-to-use)
      - 11.4.4.2.2.2 Therapeutic Application
      - 11.4.4.2.2.3 Route Of Administration
      - 11.4.4.2.2.4 Usability
      - 11.4.4.2.2.5 End User
  - 11.4.4.3 United Arab Emirates Market
    - 11.4.4.3.1 United Arab Emirates: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.4.4.3.2 United Arab Emirates: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.4.4.3.2.1 Formulation Packaging (ready-to-use)
      - 11.4.4.3.2.2 Therapeutic Application
      - 11.4.4.3.2.3 Route Of Administration
      - 11.4.4.3.2.4 Usability
      - 11.4.4.3.2.5 End User
  - 11.4.4.4 Rest of Middle East and Africa Market
    - 11.4.4.4.1 Rest of Middle East and Africa: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.4.4.4.2 Rest of Middle East and Africa: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.4.4.4.2.1 Formulation Packaging (ready-to-use)
      - 11.4.4.4.2.2 Therapeutic Application
      - 11.4.4.4.2.3 Route Of Administration
      - 11.4.4.4.2.4 Usability
      - 11.4.4.4.2.5 End User
11.5 South and Central America
- 11.5.1 South and Central America Long-Term Injectable Drug Delivery Market Overview
- 11.5.2 South and Central America: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 11.5.3 South and Central America: Long-Term Injectable Drug Delivery Market - By Segmentation
  - 11.5.3.1 Formulation Packaging (ready-to-use)
  - 11.5.3.2 Therapeutic Application
  - 11.5.3.3 Route Of Administration
  - 11.5.3.4 Usability
  - 11.5.3.5 End User
- 11.5.4 South and Central America: Long-Term Injectable Drug Delivery Market Breakdown by Countries
  - 11.5.4.1 Brazil Market
    - 11.5.4.1.1 Brazil: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.5.4.1.2 Brazil: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.5.4.1.2.1 Formulation Packaging (ready-to-use)
      - 11.5.4.1.2.2 Therapeutic Application
      - 11.5.4.1.2.3 Route Of Administration
      - 11.5.4.1.2.4 Usability
      - 11.5.4.1.2.5 End User
  - 11.5.4.2 Argentina Market
    - 11.5.4.2.1 Argentina: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.5.4.2.2 Argentina: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.5.4.2.2.1 Formulation Packaging (ready-to-use)
      - 11.5.4.2.2.2 Therapeutic Application
      - 11.5.4.2.2.3 Route Of Administration
      - 11.5.4.2.2.4 Usability
      - 11.5.4.2.2.5 End User
  - 11.5.4.3 Rest of South and Central America Market
    - 11.5.4.3.1 Rest of South and Central America: Long-Term Injectable Drug Delivery Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 11.5.4.3.2 Rest of South and Central America: Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.5.4.3.2.1 Formulation Packaging (ready-to-use)
      - 11.5.4.3.2.2 Therapeutic Application
      - 11.5.4.3.2.3 Route Of Administration
      - 11.5.4.3.2.4 Usability
      - 11.5.4.3.2.5 End User

12. Long-Term Injectable Drug Delivery Market Industry Landscape

13. Long-Term Injectable Drug Delivery Market - Key Company Profiles

13.1 Becton Dickinson and Co
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Schott AG
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Phillips-Medisize
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Gerresheimer AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 West Pharmaceutical Services Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Terumo Corp
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 SHL Medical
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Ypsomed Holding AG
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Owen Mumford Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 AptarGroup Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. List of Additional Companies Analyzed

14.1 List of Additional Companies Analyzed

15. Appendix

15.1 Glossary
15.2 Research Methodology and Approach
- 15.2.1 Secondary Research
- 15.2.2 Primary Research
- 15.2.3 Market Estimation Approach
  - 15.2.3.1 Supply Side Analysis
  - 15.2.3.2 Demand Side Analysis
- 15.2.4 Research Assumptions and Limitations
- 15.2.5 Currency Conversion
15.3 About The Insight Partners
15.4 Market Intelligence Cloud